News Roundup: NCPA Student Business Finalist, CBD Liver Toxicity Study
Here’s a roundup of the latest news coverage from Drug Topics®.
Study on Pregnant Women Points to Importance of Timely Flu Vaccination
Researchers examined the effects of severe acute respiratory infections on pregnancy and reported some concerning findings.
UAMS Team Wins 2021 Good Neighbor Pharmacy NCPA Pruitt-Schutte Student Business Plan Competition
Winners were announced during the NCPA Annual 2021 Convention.
Validcare Researchers Discuss Results of CBD Liver Toxicity Study
Co-principal investigators Jeff Lombardo and Keith Aqua discuss the unique patient profiles of the study, future cohorts, and FDA's response to the findings.
https://www.drugtopics.com/view/validcare-researchers-discuss-results-of-cbd-liver-toxicity-study
Common Oral Diuretic Pill as Alzheimer’s Treatment, Study Shows
A commonly available, FDA-approved oral diuretic pill may be a potential candidate for Alzheimer's disease treatment, according to new research.
Get to Know Good Neighbor Pharmacy and the 4 Core Value Centers
Don't miss our upcoming webinar with Good Neighbor Pharmacy, focused on helping independent pharmacies optimize their business.
https://www.drugtopics.com/view/get-to-know-good-neighbor-pharmacy-and-the-4-core-value-centers
Celebrate National Women Pharmacist Day 2021
The fourth annual Women Pharmacist Day will take place on October 12 and honor the many strides made by women in pharmacy. Head to the Drug Topics® social media pages to celebrate.
https://www.drugtopics.com/view/celebrate-national-women-pharmacist-day-october-12
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
Examining Impact of COVID-19 Diagnosis Timing on AF Progression | AHA 2024
November 21st 2024“[O]ur data do not support the hypothesis that early COVID resulted in more significant structural or electrical cardiac remodeling that would increase the likelihood of atrial fibrillation progression,” the authors said.
